News Focus
News Focus
Followers 74
Posts 15870
Boards Moderated 0
Alias Born 04/26/2010

Re: HerbieRay post# 108728

Thursday, 06/29/2017 2:47:40 PM

Thursday, June 29, 2017 2:47:40 PM

Post# of 447423
Where did you see a a 346k block trade? My software doesn't show anything close to that - biggest one yesterday was this one:

06/28/17 10:29:41 3.46 3.66 3.67 83,600

Note the terribly mismatched price/bid/ask - and after viewing the raw data more closely, this was definitely HFT bots - literally hundreds of trades took place at exactly 10:29:41, most of them of the 100 shr block variety, and NONE of them had matching price/bid/asks, although that 20 cent spread above was the highest one I can see - highly doubtful any actual humans made trades during that single second of time. This timing doesn't match with when the Jeffries upgrades came out yesterday either, was in premarket around 7:45 am:

http://thefly.com/landingPageNews.php?id=2573043

Jefferies boosts Amarin target to $7 ahead of mid-2018 data

Jefferies analyst Matthew Andrews views Amarin's risk/reward as favorable into the Vascepa mixed dyslipidemia data in mid-2018. Positive data could support a "paradigm shift" in treating the 70M mixed dyslipidemia patients with high trigylcerides and lead to broader Vascepa use, Andrews tells investors in a research note. The analyst assigns a 55% probability of positive REDUCE-IT trial data and models $1.3B in peak-adjusted sales. He sees a floor of $2 per share with negative data and long-term upside to $17 per share over the long-term with positive data. The analyst boosted his price target for Amarin shares to $7 from $5 and keeps a Buy rating on the name. The stock closed yesterday at $3.78.



The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News